Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure

Congestive Heart Failure

Volumn 9, Issue 1, 2003, Pages 9-15

  Katz, Stuart D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; ORGANIC NITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

CONGESTIVE HEART FAILURE; DISEASE COURSE; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; ERECTILE DYSFUNCTION; HUMAN; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0037233976     PISSN: 10797998     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-5299.2002.00288.x     Document Type: Review

References (76)

1. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
2. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109-142.
3. Treasure CB, Vita JA, Cox DA, et al. Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation. 1990;81:772-779.
4. Kubo SH, Rector TS, Bank AJ, et al. Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation. 1991;84:1589-1596.
5. Katz SD, Biasucci L, Sabba C, et al. Impaired endothelium-mediated vasodilation in the peripheral vasculature of patients with congestive heart failure. J Am Coll Cardiol. 1992;19:918-925.
6. Katz SD, Krum H, Khan T, et al. Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol. 1996;28:585-590.
7. Katz SD. The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Prog Cardiovasc Dis. 1995;28:23-50.
8. Le Jemtel TH, Maskin CS, Lucido D, et al. Failure to augment maximal blood flow in response to one-leg versus two-leg exercise in patients with congestive heart failure. Circulation. 1986;74:245-251.
9. Lindsay DC, Holdright DR, Clarke D, et al. Endothelial control of lower limb blood flow in chronic heart failure. Heart 1996;75:469-476.
10. Nakamura M, Ishikawa M, Funakoshi T, et al. Attenuated endothelium-dependent peripheral vasodilation and clinical characteristics in patients with chronic heart failure. Am Heart J. 1994;128:1164-1169.
11. Nakamura M, Chiba M, Ueshima K, et al. Effects of mitral and/or aortic valve replacement or repair on endothelium-dependent peripheral vasorelaxation and its relation to improvement in exercise capacity. Am J Cardiol. 1996;77:98-102.
12. Carville C, Adnot S, Sediame S, et al. Relation between impairment in nitric oxide pathway and clinical status in patients with congestive heart failure. J Cardiovasc Pharmacol. 1998;32:562-570.
13. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation. 1999;99:2118-2123.
14. Bauersachs J, Bouloumie A, Fraccarollo D, et al. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation. 1999;100:292-298.
15. Creager MA, Quigg RJ, Ren CJ, et al. Limb vascular responsiveness to beta-adrenergic receptor stimulation in patients with congestive heart failure. Circulation. 1991;83:1873-1879.
16. Zelis R, Mason DT, Braunwald E. A comparison of the effects of vasodilator stimuli on peripheral resistance vessels in normal subjects and in patients with congestive heart failure. J Clin Invest. 1968;47:960-970.
17. Katz SD, Schwarz M, Yuen J, et al. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors [see comments]. Circulation. 1993;88:55-61.
18. Maguire SM, Nugent AG, McGurk C, et al. Abnormal vascular responses in human chronic cardiac failure are both endothelium dependent and endothelium independent. Heart. 1998;80:141-145.
19. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled trial of supplemental oral L-arginine in patients with heart failure. Circulation. 1996;93:2135-2141.
20. Nakamura M, Yoshida H, Arakawa N, et al. Endothelium-dependent vasodilatation is not selectively impaired in patients with chronic heart failure secondary to valvular heart disease and congenital heart disease [see comments]. Eur Heart J. 1996;17:1875-1881.
21. Nakamura M, Arakawa N, Yoshida H, et al. Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure. Am Heart J. 1998;135:414-420.
22. Lincoln TM. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. 1989;41:479-502.
23. Supaporn T, Sandberg SM, Borgeson DD, et al. Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. Kidney Int. 1996;50:1718-1725.
24. Haneda M, Kikkawa R, Maeda S, et al. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation. Kidney Int. 1991;40:188-194.
25. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-748.
26. Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol. 1998;159:2164-2171.
27. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group [see comments] [published erratum appears in N Engl J Med. 1998;339(1):59]. N Engl J Med. 1998;338:1397-1404.
28. Chuang AT, Strauss JD, Murphy RA, et al, Sildenafil, a type-5 cGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro. J Urol. 1998;160:257-261.
29. Martin W, Furchgott RF, Villani GM, et al. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther. 1986;237:539-547.
30. DeWitt BJ, Cheng DY, McMahon TJ, et al. Analysis of responses to bradykinin in the pulmonary vascular bed of the cat. Am J Physiol. 1994;266:H2256-H2267.
31. Fineman JR, Chang R, Soifer SJ. L-Arginine, a precursor of EDRF in vitro, produces pulmonary vasodilation in lambs. Am J Physiol. 1991;261:H1563-H1569.
32. Santiago JA, Champion HC, Kadowitz PJ. T-kinin has endothelium-dependent vasodilator activity in the cat. Am J Physiol. 1997;272:H1491-H1498.
33. Packer M. Are nitrates effective in the treatment of chronic heart failure? Antagonist's viewpoint. Am J Cardiol. 1990;66:458-461.
34. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739-749.
35. Fung HL, Chung SJ, Bauer JA, et al. Biochemical mechanism of organic nitrate action. Am J Cardiol. 1992;70:4B-10B.
36. Ahlner J, Andersson RG, Torfgard K, et al. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol Rev. 1991;43:351-423.
37. Elkayam U, Karaalp IS, Wani OR, et al. The role of organic nitrates in the treatment of heart failure. Prog Cardiovasc Dis. 1999;41:255-264.
38. Cohn JN. Nitrates are effective in the treatment of chronic congestive heart failure: the protagonist's view. Am J Cardiol. 1990;66:444-446.
39. Magrini F, Niarchos AP. Ineffectiveness of sublingual nitroglycerin in acute left ventricular failure in the presence of massive peripheral edema. Am J Cardiol. 1980;45:841-847.
40. Elkayam U, Kulick D, McIntosh N, et al. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure. Circulation. 1987;76:577-584.
41. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799-804.
42. Packer M, Medina N, Yushak M, et al. Hemodynamic factors limiting the response to transdermal nitroglycerin in severe chronic congestive heart failure. Am J Cardiol. 1986;57:260-267.
43. Kulick D, Roth A, McIntosh N, et al. Resistance to isosorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction. J Am Coll Cardiol. 1988;12:1023-1028.
44. Armstrong PW, Armstrong JA, Marks GS. Pharmacokinetichemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. Circulation. 1980;62:160-166.
45. Elkayam U, Roth A, Mehra A, et al. Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure. Circulation. 1991;84:2040-2048.
46. Jordan RA, Seth L, Casebolt P, et al. Rapidly developing tolerance to transdermal nitroglycerin in congestive heart failure. Ann Intern Med. 1986;104:295-298.
47. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine [see comments]. J Am Coll Cardiol. 1990;16:923-931.
48. Roth A, Kulick D, Freidenberger L, et al. Early tolerance to hemodynamic effects of high dose transdermal nitroglycerin in responders with severe chronic heart failure. J Am Coll Cardiol. 1987;9:858-864.
49. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709-715.
50. Munzel T, Kurz S, Rajagopalan S, et al. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.
51. Axelsson KL, Ahlner J. Nitrate tolerance from a biochemical point of view. Drugs. 1987;33:63-68.
52. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol. 1983;88:71-79.
53. Ahlner J, Andersson RG, Axelsson KL, et al. Development of tolerance to glyceryl trinitrate in an isolated human peripheral vein and its relation to cyclic GMP metabolism. Acta Pharmacol Toxicol (Copenh). 1986;59:123-128.
54. Pagani ED, VanAller GS, O'Connor B, et al. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur J Pharmacol. 1993;243:141-147.
55. De Garavilla L, Pagani ED, Buchholz RA, et al. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur J Pharmacol. 1996;313:89-96.
56. Katz SD, Balidemaj K, Homma S, et al. Acute type-5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol. 2000;36:845-851.
57. Medina P, Segarra G, Martinez-Leon JB, et al. Relaxation induced by cGMP-phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. Ann Thorac Surg. 2000;70:1327-1331.
58. Osinski MT, Rauch BH, Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol. 2001; 59:1044-1050.
59. Ishikura F, Beppu S, Hamada T, et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000;102:2516-2521.
60. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25-31.
61. Grady KL, Jalowiec A, Grusk BB, et al. Symptom distress in cardiac transplant candidates. Heart Lung. 1992;21:434-439.
62. Bohachick P, Anton BB. Psychosocial adjustment of patients and spouses to severe cardiomyopathy. Res Nurs Health. 1990;13:385-392.
63. Grady KL, Jalowiec A, White-Williams C, et al. Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J Heart Lung Transplant. 1995;14:2-10.
64. Jaarsma T, Dracup K, Walden J, et al. Sexual function in patients with advanced heart failure. Heart Lung. 1996;25:262-270.
65. Muirhead J, Meyerowitz BE, Leedham B, et al. Quality of life and coping in patients awaiting heart transplantation. J Heart Lung Transplant. 1992;11:265-271; discussion 271-272.
66. Mulligan T, Sheehan H, Hanrahan J. Sexual function after heart transplantation. J Heart Lung Transplant. 1991;10:125-128.
67. Westlake C, Dracup K, Walden JA, et al. Sexuality of patients with advanced heart failure and their spouses or partners. J Heart Lung Transplant. 1999;18:1133-1138.
68. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol. 1999;83:1A-38A.
69. Conti CR, Pepine CJ, Sweeney M. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. Am J Cardiol. 1999;83:29C-34C.
70. Speakman MT, Kloner RA. Viagra and cardiovascular disease. J Cardiovasc Pharmacol Ther. 1999;4:259-267.
71. Zusman RM, Morales A, Glasser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C-44C.
72. Shakir SA, Wilton LV, Boshier A, et al. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ. 2001;322:651-652.
73. Herrmann HC, Chang G, Klugherz BD, et al. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med. 2000;342:1622-1626.
74. Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol. 2001;37:286-292.
75. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83:3C-12C.
76. DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of The Princeton Consensus Panel [editorial]. Am J Cardiol. 2000;86:175-181.